ARCT Q4 2022 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M+2666.5% YoY

Gross Profit

$133M83.2% margin

Operating Income

$121M75.8% margin

Net Income

$117M73.2% margin

EPS (Diluted)

$4.33

QoQ Revenue Growth

+1099.0%

Cash Flow

Operating Cash Flow

$160M

Free Cash Flow

$156M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$450M

Total Liabilities

$180M

Stockholders' Equity

$270M

Cash & Equivalents

$392M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$6M	+2666.5%
Gross Profit	$133M	-$25M	+634.6%
Operating Income	$121M	-$38M	+422.6%
Net Income	$117M	-$39M	+403.5%